SAN DIEGO, September 24, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.
Details of the presentations are as follows:
Event: Accelerating Pathways to Clinical Trials: An International Conference on Islet Regeneration and Replacement
Speaker: Dr. Kevin D’Amour, Vice President, Research, and Chief Scientific Officer
Date/Time: September 26, 2015; 9:00 a.m.
Location: Mayo Clinic Center for Regenerative Medicine, Rochester, Minnesota
Event: Stem Cell Meeting on the Mesa
Speaker: Dr. Paul Laikind, President and CEO
Date/Time: October 7, 2015; 11:45 a.m.
Location: Estancia La Jolla Hotel and Spa, La Jolla, California
Event: Cold Spring Harbor Asia/International Society for Stem Cell Research Joint Meeting
— Stem Cells: From Basic Biology to Disease Therapies International Symposium
Speaker: Dr. Olivia G. Kelly, Senior Director, Cell Biology
Date: October 22, 2015; 2:00 p.m.
Location: World Hotel Grand Dushu Lake Suzhou, Suzhou, China
ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goals of no immune suppression required, and a reduced risk of hypoglycemia and diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.